A practical reference on NR1D2: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
== Selected publications == Dendrosome: Dendrosomes: a novel family of vehicles for transfection and therapy. Journal of Chemical Technology & Biotechnology. Volume 75 Issue 10, Pages 919 - 922 (2000) Dendrosomes as novel gene porters-III. Journal of Chemical Technology & Biotechnology Volume 83 Issue 6, Pages 912 - 920 (2008) Structural biology: Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Letters Volume 557 Issue 1-3, Pages 104-108 (2004) Solution structure of long neurotoxin NTX-1 from the venom of Naja naja oxiana by 2D-NMR spectroscopy. European Journal of Biochemistry Volume 271 Issue 23-24 Pages 4950-4957 (2004) Biomaterials: Synthesis and thermal behavior of triblock copolymers from L-lactide and ethylene glycol with long center PEG block. Journal of Applied Polymer Science Volume 68 Issue 12 Pages 1949-1954 (1998) Synthesis and characterization of novel biodegradable triblock copolymers from L-lactide, glycolide, and PPG. Journal of Applied Polymer Science Volume 73 Issue 5 Pages 633-637 (1999) Synthesis and characterization of ABA triblock and novel multiblock copolymers from ethylene glycol, L-lactide, and epsilon-caprolactone. Journal of Applied Polymer Science Volume 83 Issue 10 Pages 2072-2081 (2002) Mass preparation and characterization of alginate microspheres. Process Biochemistry Volume 35 Issue 9 Pages 885-888 (2000) Membranes: A simple method for preparation of immuno-magnetic liposomes.
Cohen (1952), former co-owner of the Boston Celtics and the Brooklyn Nets; former chairman and CEO of the Madison Square Garden Corporation Lawrence K. Grossman (1952), president of PBS 1976–1984 and NBC News 1985–1988 Richard Wald (1952), former president of NBC News 1973–1977 Robert A. Belfer (1955), oilman and philanthropist, namesake of the Belfer Center for Science and International Affairs at Harvard University Thomas Ludlow Chrystie II (1955), first chief financial officer of Merrill Lynch & Company and creator of the Cash Management Account Alfred Lerner (1955), chairman of MBNA Bank and ex-owner of the Cleveland Browns Richard Ravitch (1955), chairman of the Metropolitan Transportation Authority and the Bowery Savings Bank Sid Sheinberg (1955), head of Universal Pictures Barry F. Sullivan (1955), chairman and CEO of First Chicago Bank, deputy mayor of New York City under David Dinkins Edward Botwinick (1956), IT entrepreneur and inventor, co-founder of Timeplex Franklin A. Thomas (1956), former president of The Ford Foundation James R. Barker (1957), chairman of Interlake Steamship Company, former chairman and CEO of Moore-McCormack Peter L.
The samples were originally taken to test for preventable diseases, but with the advance in genomic sequencing technologies many samples are being kept for DNA identification and research, increasing the possibility that more children will be opted out of newborn screening from parents who see the kept samples as a form of research done on their child.
Sources: en.wikipedia.org
== Revisionism == The role of the United States in the Vietnam War disillusioned New Left historians and created many historians with sympathy towards the Viet Cong communist position and antipathy towards American policies. Much more important were the revisionists who argued that both United States and the Soviet Union were responsible for blundering into the war and rejected the premises of "containment". They battled the "orthodox" historians. "Revisionist" accounts emerged in the wake of the Vietnam War in the context of a larger rethinking of the United States role in international affairs, which was seen more in terms of American empire or hegemony. In the specific context of the Vietnam War, this "revisionist" narrative became the historiographical orthodoxy, whereas revisionism in Vietnam War historiography came to defend the US policy of containment. While the new school of thought spanned many differences among individual scholars, the works comprising it were generally responses in one way or another to William Appleman Williams 1959 volume, The Tragedy of American Diplomacy. Williams challenged the long-held assumptions of "orthodox" accounts, arguing that Americans had always been an empire-building people even while American leaders denied it. The influence of Williams, who taught at the University of Wisconsin–Madison, and several of his students who subsequently published works on these themes, was enough to create what became known as the Wisconsin School of American diplomatic history.
=== Reductive elimination step === In order for R1-R2 to reductively eliminate, these groups must occupy mutually cis coordination sites. Any trans-adducts must therefore isomerize to the cis intermediate or the coupling will be frustrated. A variety of mechanisms exist for reductive elimination and these are usually considered to be concerted. First, the 16-electron tetravalent intermediate from the transmetalation step can undergo unassisted reductive elimination from a square planar complex. This reaction occurs in two steps: first, the reductive elimination is followed by coordination of the newly formed sigma bond between R1 and R2 to the metal, with ultimate dissociation yielding the coupled product.
Similar structures include the 310 helix (i + 3 → i hydrogen bonding) and the π-helix (i + 5 → i hydrogen bonding). The α-helix can be described as a 3.613 helix, since the i + 4 spacing adds three more atoms to the H-bonded loop compared to the tighter 310 helix, and on average, 3.6 amino acids are involved in one ring of α-helix. The subscripts refer to the number of atoms (including the hydrogen) in the closed loop formed by the hydrogen bond.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.